Pages that link to "Q44873739"

The following pages link to Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice (Q44873739):

Displaying 30 items.

• Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets (Q26830569) (← links)
• New pharmacological strategies in rheumatic diseases (Q28073763) (← links)
• Re-administration of abatacept for the control of articular symptoms of rheumatoid arthritis during anti-tuberculous therapy (Q33652552) (← links)
• How "humane" is your endpoint? Refining the science-driven approach for termination of animal studies of chronic infection. (Q34139921) (← links)
• Inhibition of T cells provides protection against early invasive pneumococcal disease (Q34309777) (← links)
• Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective (Q35237588) (← links)
• Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice. (Q36298389) (← links)
• Translating co-stimulation blockade into clinical practice. (Q36972500) (← links)
• Mycobacterial disease in patients with rheumatic disease (Q37335860) (← links)
• Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNFα neutralization. (Q37420149) (← links)
• Abatacept therapy and safety management (Q37533319) (← links)
• Safety of biologic therapy in rheumatoid arthritis (Q37944433) (← links)
• Abatacept therapy and safety management (Q38006176) (← links)
• Overview of safety of non-biologic and biologic DMARDs (Q38065768) (← links)
• Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy (Q38116751) (← links)
• Safety profile of biological therapies for treating rheumatoid arthritis (Q38665700) (← links)
• Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis (Q38993229) (← links)
• Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry (Q40864639) (← links)
• Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides (Q41176187) (← links)
• CTLA4 Immunoglobulin but Not Anti-Tumor Necrosis Factor Therapy Promotes Staphylococcal Septic Arthritis in Mice. (Q41358884) (← links)
• Antibiotic-killed Staphylococcus aureus induces destructive arthritis in mice (Q41706624) (← links)
• Tuberculosis in CBA/J mice (Q42269144) (← links)
• Treatment with Biologicals in Rheumatoid Arthritis: An Overview. (Q47132835) (← links)
• Interrupting oral infection of Porphyromonas gingivalis with anti-FimA antibody attenuates bacterial dissemination to the arthritic joint and improves experimental arthritis (Q51736334) (← links)
• [Selective co-stimulation blockade. CTLA4-Ig (Abatacept)]. (Q52902186) (← links)
• [Risk of infection by biologics] (Q81402998) (← links)
• [A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation] (Q83398658) (← links)
• Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis (Q90582460) (← links)
• The YIN and YANG of lipoproteins in developing and preventing infectious arthritis by Staphylococcus aureus (Q92936984) (← links)
• Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors (Q96953884) (← links)